KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Cash (2016 - 2025)

Historic Change in Cash for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $61.1 million.

  • CRISPR Therapeutics AG's Change in Cash fell 1587.77% to $61.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $49.3 million, marking a year-over-year increase of 15400.47%. This contributed to the annual value of $49.3 million for FY2025, which is 15400.47% up from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Change in Cash stood at $61.1 million for Q4 2025, which was down 1587.77% from $92.9 million recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Change in Cash peaked at $521.8 million during Q2 2021, and registered a low of -$636.3 million during Q3 2021.
  • For the 5-year period, CRISPR Therapeutics AG's Change in Cash averaged around -$41.3 million, with its median value being -$42.1 million (2021).
  • Its Change in Cash has fluctuated over the past 5 years, first tumbled by 69529.89% in 2021, then surged by 312698.76% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Change in Cash (Quarter) stood at -$88.5 million in 2021, then plummeted by 223.64% to -$286.3 million in 2022, then surged by 51.61% to -$138.5 million in 2023, then soared by 152.4% to $72.6 million in 2024, then fell by 15.88% to $61.1 million in 2025.
  • Its last three reported values are $61.1 million in Q4 2025, $92.9 million for Q3 2025, and -$41.6 million during Q2 2025.